MSK
Search
- Page Path
- HOME > Search
Journal Article
- Efficacy of A/H1N1/2009 split inactivated influenza A vaccine (GC1115) in mice and ferrets
- Hae Jung Han , Min-Suk Song , Su-Jin Park , Han Yeul Byun , Norbert John C. Robles , Suk-Hoon Ha , Young Ki Choi
- J. Microbiol. 2019;57(2):163-169. Published online January 31, 2019
- DOI: https://doi.org/10.1007/s12275-019-8504-1
- 58 View
- 0 Download
- 4 Web of Science
- 4 Crossref
-
Abstract
- To evaluate the efficacy of a non-adjuvant A/H1N1/2009 influenza A vaccine (GC1115), we demonstrated the immunogenicity and protective efficacy of GC1115 in mouse and ferret models. The immunogenicity of GC1115 was confirmed after intramuscular administration of 1.875, 3.75, 7.5, and 15 μg hemagglutinin antigen (HA) in mice and 7.5, 15, and 30 μg HA in ferrets at 3-week intervals. A single immunization with GC1115 at HA doses > 7.5 μg induced detectable seroconversion in most mice, and all mice given a second dose exhibited high antibody responses in a dose-dependent manner. The mice in the mock (PBS) and 1.875 μg HA immunized groups succumbed by 13 days following A/California/ 04/09 infection, while all mice in groups given more than 3.75 μg HA were protected from lethal challenge with the A/California/04/09 virus. In ferrets, although immunization with even a single dose of 15 or 30 μg of HA induced detectable HI antibodies, all ferrets given two doses of vaccine seroconverted and exhibited HI titers greater than 80 units. Following challenge with A/California/04/09, the mock (PBS) immunized ferrets showed influenza-like clinical symptoms, such as increased numbers of coughs, elevated body temperature, and body weight loss, for 7 days, while GC1115- immunized ferrets showed attenuated clinical symptoms only for short time period (3–4 days). Further, GC1115-immunized ferrets displayed significantly lower viral titers in the upper respiratory tract (nasal cavity) than the mock vaccinated group in a dose-dependent manner. Taken together, this study demonstrates the immunogenicity and protective efficacy of GC1115 as a non-adjuvanted vaccine.
-
Citations
Citations to this article as recorded by
- Dose sparing enabled by immunization with influenza vaccine using orally dissolving film
Keon-Woong Yoon, Ki Back Chu, Gi-Deok Eom, Jie Mao, Su In Heo, Fu-Shi Quan
International Journal of Pharmaceutics.2024; 667: 124945. CrossRef - Ferrets as a model for tuberculosis transmission
Tuhina Gupta, Naveen Somanna, Thomas Rowe, Monica LaGatta, Shelly Helms, Simon Odera Owino, Tomislav Jelesijevic, Stephen Harvey, Wayne Jacobs, Thomas Voss, Kaori Sakamoto, Cheryl Day, Christopher Whalen, Russell Karls, Biao He, S. Mark Tompkins, Abhijeet
Frontiers in Cellular and Infection Microbiology.2022;[Epub] CrossRef - AddaVax Formulated with PolyI:C as a Potential Adjuvant of MDCK-based Influenza Vaccine Enhances Local, Cellular, and Antibody Protective Immune Response in Mice
Xuanxuan Nian, Jiayou Zhang, Tao Deng, Jing Liu, Zheng Gong, Chuanshuo Lv, Luyao Yao, Junying Li, Shihe Huang, Xiaoming Yang
AAPS PharmSciTech.2021;[Epub] CrossRef - The Intersection of Age and Influenza Severity: Utility of Ferrets for Dissecting the Age-Dependent Immune Responses and Relevance to Age-Specific Vaccine Development
Melissa Rioux, Magen E. Francis, Cynthia L. Swan, Anni Ge, Andrea Kroeker, Alyson A. Kelvin
Viruses.2021; 13(4): 678. CrossRef
- Dose sparing enabled by immunization with influenza vaccine using orally dissolving film
First
Prev
TOP
